Merck Eurolab name change to VWR International
Merck KGaA's scientific supplies unit Merck Eurolab will officiallychange its name to VWR International, effective January 1, 2002.
VWR International, with operations in 18 countries and annual sales of $2.4 billion, was formed in January this year when Merck combined its two wholly-owned laboratory distribution units, VWR Scientific Products of the USA and Merck Eurolab Group based in Belgium. According to VWR chief executive Walter Zywottek, "understandably many of our European regional operations have continued to us their pre-VWR names to maintain familiarity for their regional and local customer bases. But we think the marketplace is now ready for our organization to trade as a single brand."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze